[go: up one dir, main page]

MX2011011871A - Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina. - Google Patents

Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina.

Info

Publication number
MX2011011871A
MX2011011871A MX2011011871A MX2011011871A MX2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A
Authority
MX
Mexico
Prior art keywords
amount
theanine
water
soluble
acetylsalicylic acid
Prior art date
Application number
MX2011011871A
Other languages
English (en)
Inventor
Harry G Brittain
Philip V Felice
Original Assignee
Soluprin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soluprin Pharmaceuticals Inc filed Critical Soluprin Pharmaceuticals Inc
Publication of MX2011011871A publication Critical patent/MX2011011871A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una composición de co-cristal de aspirina-teanina soluble en agua que incluye una cantidad de ácido acetilsalicílico y una cantidad de un enantiómero de teanina asociada con la cantidad de ácido acetilsalicílico. La composición puede crearse por un método que incluye las etapas de: (i) proporcionar una cantidad de ácido acetilsalicílico; (ii) agregar una cantidad de un enantiómero de teanina a la cantidad de ácido acetilsalicílico para formar una mezcla que comprende la cantidad de ácido acetilsalicílico y el enantiómero de teanina; (iii) humectar la mezcla y (iv) moler la mezcla por una longitud de tiempo suficiente para producir una masa cristalina seca. La composición de co-cristal soluble en agua es apropiada para administración intravenosa, preferentemente en humanos.
MX2011011871A 2009-05-08 2009-06-23 Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina. MX2011011871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/437,735 US8173625B2 (en) 2009-05-08 2009-05-08 Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
PCT/US2009/048275 WO2010128977A1 (en) 2009-05-08 2009-06-23 Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine

Publications (1)

Publication Number Publication Date
MX2011011871A true MX2011011871A (es) 2012-03-06

Family

ID=43050309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011871A MX2011011871A (es) 2009-05-08 2009-06-23 Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina.

Country Status (12)

Country Link
US (11) US8173625B2 (es)
EP (1) EP2427196B1 (es)
JP (1) JP5568127B2 (es)
KR (1) KR101603368B1 (es)
CN (1) CN102421438B (es)
CA (1) CA2760555C (es)
EA (1) EA022058B1 (es)
IL (1) IL215922A (es)
MX (1) MX2011011871A (es)
NZ (1) NZ596200A (es)
SG (1) SG175921A1 (es)
WO (1) WO2010128977A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173625B2 (en) * 2009-05-08 2012-05-08 Theaprin Pharmaceuticals Inc. Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
ITMI20120586A1 (it) 2012-04-11 2013-10-12 Milano Politecnico Co-cristalli di 3-iodiopropinil butilcarbammato
GB201311984D0 (en) * 2013-07-04 2013-08-21 Univ Cardiff Methods and compounds for preventing or treating osteoarthritis
RU2539350C1 (ru) * 2013-12-24 2015-01-20 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) Сокристаллическая форма 2-гидроксибензамида с салициловой кислотой
US9896429B2 (en) 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
EP3148982A1 (en) 2014-05-27 2017-04-05 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US10508096B2 (en) 2014-05-27 2019-12-17 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US10066056B2 (en) 2014-06-19 2018-09-04 Sabic Global Technologies B.V. Brominated cross-linkable polycarbonate compositions
US9603937B2 (en) 2015-03-09 2017-03-28 Theaprin Pharmaceuticals Inc. Platform drug delivery system utilizing crystal engineering and theanine dissolution
DK3379952T3 (da) 2015-11-25 2024-01-08 Reynolds Tobacco Co R Nikotinsalte, co-krystaller og salt-co-krystalkomplekser
US10376464B2 (en) * 2015-11-25 2019-08-13 Theaprin Pharmaceuticals Inc. Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine
KR102397334B1 (ko) * 2016-06-28 2022-05-11 아사메딕 에이에스 2성분 조성물
CA3101168A1 (en) * 2017-05-30 2018-12-06 Theaprin Pharmaceuticals, Inc. Sublingual formulation with water-soluble cocrystals of acetylsalicylic acid with citric acid, sodium bicarbonate, and l-theanine for the treatment of acute myocardial infarction
EP4635478A2 (en) 2017-09-05 2025-10-22 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
CA3178188A1 (en) * 2020-05-08 2021-11-11 Philip V. Felice Cocrystal antioxidants of protocatechuic acid with l-theanine for the treatment of oxidative stress and inflammatory conditions
CN111870558B (zh) * 2020-08-17 2022-07-12 山东华熙海御生物医药有限公司 一种抑制透明质酸酶活性的组合物及皮肤护理产品
WO2022231998A1 (en) * 2021-04-27 2022-11-03 Theaprin Pharmaceuticals, Inc. Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use
TWI834984B (zh) * 2021-07-30 2024-03-11 寶齡富錦生技股份有限公司 控制釋放口服製劑及其製備方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157030A (en) * 1989-08-25 1992-10-20 Alexander Galat Rapidly soluble aspirin compositions and method
US5723453A (en) * 1995-11-13 1998-03-03 Health Corporation Stabilized, water-soluble aspirin composition
US5665388A (en) * 1995-11-13 1997-09-09 Health Corporation Method for preparation of an alkaline and aspirin combination compound
US5776431A (en) * 1997-03-26 1998-07-07 Galat; Alexander Water-soluble aspirin composition
US6665388B2 (en) * 2000-12-20 2003-12-16 Bellsouth Intellectual Property Corporation System and method for monitoring incoming communications to a telecommunications device
WO2002096870A2 (en) 2001-05-31 2002-12-05 The Regents Of The University Of California Sponge-derived terpenoids and methods of use
DE10202019A1 (de) * 2002-01-18 2003-07-24 Bayer Ag Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
US20060292225A1 (en) * 2005-06-24 2006-12-28 Felix Arthur M Water soluble analgesic formulations and methods for production
CA2643860A1 (en) * 2006-03-23 2007-09-27 Herbalscience Singapore Pte. Ltd. Extracts and methods comprising green tea species
US8173625B2 (en) 2009-05-08 2012-05-08 Theaprin Pharmaceuticals Inc. Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine

Also Published As

Publication number Publication date
JP5568127B2 (ja) 2014-08-06
US20130012482A1 (en) 2013-01-10
US9289439B2 (en) 2016-03-22
US9289440B2 (en) 2016-03-22
US20140296189A1 (en) 2014-10-02
CA2760555A1 (en) 2010-11-11
KR101603368B1 (ko) 2016-03-14
EP2427196A4 (en) 2012-10-17
SG175921A1 (en) 2011-12-29
US20140288029A1 (en) 2014-09-25
CN102421438B (zh) 2014-04-02
US20130345183A1 (en) 2013-12-26
KR20120011031A (ko) 2012-02-06
CN102421438A (zh) 2012-04-18
US20140179644A1 (en) 2014-06-26
US9289438B2 (en) 2016-03-22
EP2427196A1 (en) 2012-03-14
US20130123218A1 (en) 2013-05-16
US8476250B2 (en) 2013-07-02
IL215922A (en) 2014-06-30
EA022058B1 (ru) 2015-10-30
JP2012526105A (ja) 2012-10-25
US20120190655A1 (en) 2012-07-26
HK1164162A1 (en) 2012-09-21
US8173625B2 (en) 2012-05-08
US20140235594A1 (en) 2014-08-21
CA2760555C (en) 2014-08-19
US20140343021A1 (en) 2014-11-20
EP2427196B1 (en) 2015-11-04
IL215922A0 (en) 2011-12-29
US8304404B2 (en) 2012-11-06
US20140148418A1 (en) 2014-05-29
NZ596200A (en) 2013-04-26
EA201101458A1 (ru) 2012-05-30
AU2009345832A1 (en) 2011-11-17
WO2010128977A1 (en) 2010-11-11
US8685948B2 (en) 2014-04-01
US20100286099A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
MX2011011871A (es) Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina.
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
ECSP13012966A (es) Derivados de acido 3-fenilpropionoco ramificados y su uso
AR086237A1 (es) FORMULACION PARA ANTICUERPO ANTI-a4b7
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
TN2012000543A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
WO2014066468A8 (en) Stable, low viscosity antibody formulation
NZ599594A (en) Fast dissolving solid dosage form
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
EA201171399A1 (ru) Способ и композиция для улучшения всасывания лекарственных средств
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
DK2007429T3 (da) Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
MX390947B (es) Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
MX2016006727A (es) Composiciones farmaceuticas con actividad hidratante y lubricante.
CL2011000420A1 (es) Ester ter-butilico del acido [6-(5-etoximetoxi-benzofuran-2-il)-2-nitro-piridin-3-il]-metil-carbamico; proceso de preparacion; ester ter-butilico del acido [5-(5-etoximetoxi-benzofuran-2-il)-6-nitro-piridin-2-il]-metilcarbamico; y su uso como precursor para preparar un compuesto marcado.
WO2009020104A1 (ja) アデニン化合物を含有するゲル状外用組成物
CL2010000226A1 (es) Metodo para retardar la maduracion de un cultivo aplicando una mezcla de una fuente fosforosa, y una fuente de acido giberelico; y metodo para retardar la maduracion de un cultivo incorporando una composicion en un revestimiento.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ABBVIE INC.

FG Grant or registration